Creatinine News and Research

RSS

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Proteinuria common in canine lymphoma

Approximately a quarter of dogs with lymphoma have proteinuria, a much greater proportion than seen in healthy dogs, indicate research results.

16 Jan 2013

BPA adversely affects kidney function in children

Children with high levels of exposure to bisphenol A are at increased risk for low-grade albuminuria, report researchers.

16 Jan 2013

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

2 Jan 2013

Anesthesia choice may benefit knee arthroplasty patients

Spinal anesthesia could reduce the risk for postoperative complications in select patients undergoing total knee arthroplasty, US researchers say.

28 Dec 2012

Concern over transfusions in myocardial infarction patients

A meta-analysis highlights the consistent observational finding that patients with myocardial infarction who receive blood transfusions are at high risk for dying.

28 Dec 2012

Continuous vancomycin optimizes neonate therapy

Researchers recommend that a patient-tailored dosing regimen is used routinely in neonates for continuous infusion therapy of the antibiotic, vancomycin.

24 Dec 2012

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.

18 Dec 2012

Concern over enoxaparin bleeding risk in patients with moderate renal impairment

The low molecular weight heparin enoxaparin is associated with an increased risk for major bleeding in patients who have moderate renal impairment, say US scientists in findings that have prompted calls for updates to dosing recommendations.

14 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread (tenofovir disoproxil fumarate).

28 Nov 2012

Kidney disease measures on mortality, ESRD unaffected by age

Regardless of age, estimated glomerular filtration rate and high albuminuria are linked to death and end-stage renal disease, say US scientists who found a lower relative but higher absolute mortality risk difference at older age.

23 Nov 2012

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.

15 Nov 2012

Tolvaptan improves kidney health in polycystic kidney disease

A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.

12 Nov 2012

Antibiotic choices critical for elderly with bloodstream infections

Failure to treat patients with bacteremia with an appropriate antibiotic is particularly harmful in elderly patients, report researchers.

8 Nov 2012

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.

1 Nov 2012

LVEDP-guided hydration effectively prevents CI-AKI in patients undergoing cardiac catheterization

A hydration regimen tailored to the patient's fluid status was effective in reducing damage to kidneys in patients undergoing cardiac catheterization, according to a study presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

26 Oct 2012

Warning against colloids in fluid resuscitation

Hydroxyethyl starch offers no benefits over saline for fluid resuscitation in critically ill patients and may have renal consequences, shows a randomized trial.

23 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012